Lipocurc is under clinical development by SignPath Pharma and currently in Phase II for Prostate Cancer. According to GlobalData, Phase II drugs for Prostate Cancer have a 23% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Lipocurc’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Lipocurc overview
Liposomal curcumin is under development for the treatment of metastatic cancer, advanced solid tumors including non-small cell lung carcinoma, prostate cancer, colon cancer, glioblastoma multiforme, high-grade glioma, astrocytoma, gliosarcoma, mesothelioma, multiple myeloma, sepsis, Parkinson's disease and coronavirus disease 2019 (COVID-19). The drug candidate is administered through intravenous infusion and acts by targeting HDAC. It is a nanoparticle-sized liposomal formulation.
See Also:
It was also under development for the treatment of psoriasis, pancreatic cancer and Ebola viral infections.
SignPath Pharma overview
SignPath Pharma develops curcumin based drugs to treat cancer and cardiac side effects. The company is investigating its lead products SPP4040, a cancer supportive care drug to reduce cardiomyopathy caused due to cancer chemotherapy; and LipoCurc, a liposomal synthetic curcumin formulation targeting glioblastoma, multiple myeloma, and other cancer indications. It is also evaluating LipoCurc for the treatment of sepsis and COVID-19. SignPath Pharma utilizes CorreQT, its proprietary platform technology to create lipid based drugs that mitigate cardiac side effects. The company works in partnership with labs, hospitals, and other companies in Canada, Europe, the US, and Asia. SignPath Pharma is headquartered in Sandy, Utah, the US.
For a complete picture of Lipocurc’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
